Tissue plasminogen activator glycosylation variants with improved therapeutic properties
US5612029A · kind A · utility
17Cited by
25References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 1995 |
| Grant date | Mar 18, 1997 |
| Priority date | — |
| Expiry date | May 8, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns tissue plasminogen activator (t-PA) variants which are glycosylated at any of positions 103-105, and are devoid of functional carbohydrate structure at position 117 of wild-type human t-PA amino acid sequence. The variants have extended circulatory half-life and substantially retained fibrin binding, or improved in vivo fibrinolytic potency, as compared to wild-type human t-PA.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.